Ribociclib is classified as a CDK 4/6 inhibitor (cyclin-dependent kinase 4/6 inhibitor).IT’s used in combination with:
- an aromatase inhibitor to treat pre/perimenopausal or postmenopausal women with hormone receptor HR+(HR-positive), human epidermal growth factor receptor 2 HER2-(HER2-negative) breast cancer that has spread to other parts of the body (metastatic), as the first endocrine-based therapy; or
- fulvestrant to treat postmenopausal women with HR-(HR-positive),HER2-(HER2-negative) metastatic breast cancer as the first endocrine-based therapy or with disease progression following endocrine therapy.
Ribociclib sold as the trade name Kisqali in developed country.
Ribociclib has generic form of several brands include:
- LUCIUS Pharma（Suspected illegal manufacturer）：LUCIRIBOC 200
Brand Name : KRYXANA
Composition : Ribociclib 200mg
Indication: Antineoplastic-CDK 4/6 inhibitor
Form : Tablets (Oral administration)
Packing : 21 Tablets in 1 box
Manufactured By:Novartis [India]
Storage:Store at room temperature (10-30°C)